Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial

Gastroenterology

Volumn 124, Issue 5, 2003, Pages 1202-1209

  Gionchetti, Paolo ^a,b   Rizzello, Fernando ^a   Helwig, Ulf ^a   Venturi, Alessandro ^a   Lammers, Karen Manon ^a   Brigidi, Patrizia ^a   Vitali, Beatrice ^a   Poggioli, Gilberto ^a   Miglioli, Mario ^a   Campieri, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL 3;

ADULT; ARTICLE; BIFIDOBACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FECES CULTURE; FECES MICROFLORA; FEMALE; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; ILEOSTOMY; ILEUM POUCH; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTESTINE ANASTOMOSIS; KAPLAN MEIER METHOD; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS;

EID: 0038185270     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00171-9     Document Type: Article

References (41)

1. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994;107:1856-1860.
2. Svaninger G, Nordgren S, Oresland T, Hulten L. Incidence and characteristics of pouchitis in the Koch continent ileostomy and the pelvic pouch. Scand J Gastroenterol 1993;28:695-700.
3. Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-239.
4. Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, Löfberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996;39:1012-1018.
5. Meagher AP, Farouk R, Dozois R, Kelly KA, Pemberton JH. J-ileal pouch-anal anastomosis for CUC: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800-803.
6. Fazio VW, O'Riordain MG, Lavery IC, Church JM, Lau P, Strong SA, Hull TL. Long-term functional outcome and quality of life after stapled restorative proctocolectomy. Ann Surg 1999;230:575-584.
7. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000;24:851-856.
8. Sandborn WJ. Pouchitis: definition, risk factors, frequency, natural history, classification, and public perspectives, In: McLeod RS, Martin F, Sutherland LR, Wallace JL, Williams CN, eds. Trends in inflammatory bowel disease. Lancaster, England: Kluwer, 1997:51-63.
9. Madden M, McIntyre A, Nicholls RJ. Double blind cross-over trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193-1196.
10. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713-718.
11. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzy FH, Brzezinsky A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-305.
12. Sheperd NA, Jass JR, Dural I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy. J Clin Pathol 1987;40:601-607.
13. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994;69:409-415.
14. Schaafsma G. State of the art concerning probiotic strains in milk products. IDF Nutr Newslett 1996;5:23-24.
15. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999;116:1246-1249.
16. Shanahan F. Probiotics in inflammatory bowel diseases. Gut 2001;48:609.
17. Fabia R, Ar'Rajab A, Johansson M-L, Willén R, Andersson R, Molin G, Bengmark S. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 1993;28:155-162.
18. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, Jeppsson B. The effects of Lactobacillus strains and oat fibre on methotrexate-induced enterocolitis in rats. Gastroenterology 1996;111:334-344.
19. Madsen KL, Doyle JSG, Jewell LD, Tavernini MM, Fedorak RN Lactobacillus species prevents colitis in interleukin-10 gene-deficient mice. Gastroenterology 1999;116:1107-1114.
20. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, Sartor RB. Lactobacillus plantarum 299Vs in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 2002;8:71-80.
21. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O'Sullivan G, Shanahan F, Collins JK. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219-1225.
22. Murphy L, Byrne F, Collins JK, Shanahan F, O'Sullivan GC, Aranda R. Evaluation and characterisation of probiotic therapy in the CD45Rbhi transfer model of colitis. Gastroenterology 1999;116: A3382 (abstr).
23. Kruis W, Schuts E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
24. Rembacken BJ, Snelling AM, Hawkey PM, Axon ATR. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999;354:635-639.
25. Kruis W, Fric P, Stolte M. The Mutaflor Study Group. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 2001;120:A680 (abstr).
26. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-309.
27. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalicylic acid (5-ASA). Aliment Pharmacol Ther 1999;13:1103-1108.
28. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, Amadini C, Romboli E, Gionchetti P. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's diseasea randomized controlled study vs mesalamine. Gastroenterology 2000;118:A4179 (abstr)
29. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-591.
30. Tiplady B. A basic program for constructing a dispensing list for a randomized clinical trial. Br J Clin Pharmacol 1981;11:617-618.
31. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-810.
32. Summanen P, Baron EJ, Summanen P, Baron ES, Citron DM, Strong C, Wexler HM, Finegold SM, eds. Wadswort anaerobic bacteriology manual. 5th ed. Singapore: STAR, 1993.
33. Hartemink R, Domenech VR, Rombouts FM. LAMVAB: a new selective medium for the isolation of lactobacilli from feces. J Microb Methods 1997;29:77-84.
34. Hartemink R, Kok BJ, Weenk GH, Rombouts FM. Raffinose-Bifidobacterium (RB) agar, a new selective medium for bifidobacteria. J Microb Methods 1996;27:33-43.
35. Dave RI, Shah NP. Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, and bifidobacteria. J Dairy Sci 1996;76:1529-1536.
36. Timisjärvi AT, Alatossava T. Development of oligonucleotide primers from the 16S-23S rRNA intergenic sequences for identifying different dairy and probiotic lactic acid bacteria by PCR. Int J Food Microbiol 1997;35:49-56.
37. Kok RG, De Wall A, Schut F, Welling GW, Weenk G, Hellingwerf KJ. Specific detection and analysis of a probiotic Bifidobacterium strain in infant faeces. Appl Environ Microbiol 1996;62:3668-3672.
38. Brigidi P, Vitali B, Swennen E, Altomare L, Rossi M, Matteuzzi D. Specific detection of Bifidobacterium strains in a new probiotic preparation and in human feces by polymerase chain reaction. Syst Appl Microbiol 2000;23:391-399.
39. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001;152:735-741.
40. Ruseler-van-Embden JGH, Schouten WR, van Lieshout LMC. Pouchitis: result of microbial imbalance? Gut 1994;114:35:658-664.
41. Ulisse S, Gionchetti P, D'Alo S, Russo FP, Pesce I, Ricci G, Rizzelio F, Helwig U, Cifone MG, Campieri M, De Simone C. Expression of cytokines, inducible nitric oxide synthetase and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001;96:2691-2699.